ANAHEIM, Calif.--After one year taking green tea catechins
(GTCs), only one in a group of 32 men at high risk of developing
prostate cancer were diagnosed with the disease, compared to
nine out of 30 in a control group. Italian researchers found
epigallocatechin gallate (EGCG) in GTCs targeted prostate cancer
cells for death, without damaging benign controls. The outcome
were reported at the 96th Annual Meeting of the American
Association for Cancer Research in Anaheim, Calif.
Italian researchers from the University of Parma, University of
Modena, Reggio Emilia and Saverio
Bettuzzi found Clusterin, a gene involved in prostate apoptosis,
a possible mediator of catechins' action. "EGCG induced death in
cancer cells, not normal cells, inducing Clusterin expression,"
said Bettuzzi. The research subjects were aged 45 to 75 with
high-grade prostatic intraepithelial neoplasia--malignant
lesions that are prostate cancer precursors--for which no
treatment had been given, and who were not consuming green tea,
tea-derived products or antioxidants, or following
anti-androgenic therapy. Intervention subjects received 200 mg
of GTCs (50 percent EGCG). The 30 percent incidence rate of
prostate cancer in the control group was consistent with
previous findings, as was the absence of significant side
effects or adverse reactions among the treated group.
In closing, it will benefit you to seek out other resources on
this topic if you feel that you don’t yet have a firm
understanding of the subject matter.
Read more about natural prostate health supplement - Prostacet